{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005516","form_type":"8-K","ticker":"AGL","cik":"0001831097","company_name":"agilon health, inc.","filed_at":"2023-03-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.905771+00:00","generated_at":"2026-06-18T18:46:05.885220+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"agilon health Q4 revenue up 49% to $690M; FY2022 Adjusted EBITDA turns positive; guides 2023 EBITDA $75-90M","bullets":["Q4 revenue $690M (+49% YoY); FY2022 revenue $2.71B (+48%). Medicare Advantage members 269,500 (+45%).","Q4 medical margin $61M (+93%); FY2022 medical margin $305M (+67%). Medical margin rate 8.8% Q4, 11.2% FY.","Q4 net loss $57M (flat YoY); FY2022 net loss $107M vs $407M (includes $292M non-cash stock comp in 2021).","FY2022 Adjusted EBITDA positive $4M vs negative $39M; Q4 Adjusted EBITDA negative $11M vs negative $27M.","Completed acquisition of mphrX on Feb 28, 2023; expects 2023 revenue $4.28-4.37B, Adjusted EBITDA $75-90M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005516","json":"https://secwatch.observer/filing/0000950170-23-005516.json","markdown":"https://secwatch.observer/filing/0000950170-23-005516.md","text":"https://secwatch.observer/filing/0000950170-23-005516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831097/000095017023005516/0000950170-23-005516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831097/000095017023005516/agl-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T18:46:05.885220+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f15c46240801183ca65a7ecb50b400dd82ace99","claim":"agilon health, inc. reported the quarter ended December 31, 2022 results: revenue $690 million, net income Net loss of $57 million. Guidance initiated.","evidence_excerpt":"Total revenue of $690 million increased 49% during the fourth quarter compared to $463 million in the fourth quarter 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831097/000095017023005516/0000950170-23-005516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$690 million"},{"label":"Net income","value":"Net loss of $57 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ce754b17bdca4b34ae83f83392ae0a6df69fafbe","claim":"agilon health, inc. reported the fiscal year ended December 31, 2022 results: revenue $2.71 billion, net income Net loss of $107 million. Guidance initiated.","evidence_excerpt":"For the fiscal year 2022, total revenue of $2.71 billion increased 48% compared to $1.83 billion in the comparable 2021 period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831097/000095017023005516/0000950170-23-005516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$2.71 billion"},{"label":"Net income","value":"Net loss of $107 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}